113 related articles for article (PubMed ID: 15317463)
21. A new strategy for the construction of the imidazo[1,5-a]quinoxalin-4-one ring system and its application to the efficient synthesis of BMS-238497, a novel and potent Lck inhibitor.
Chen BC; Zhao R; Bednarz MS; Wang B; Sundeen JE; Barrish JC
J Org Chem; 2004 Feb; 69(3):977-9. PubMed ID: 14750833
[TBL] [Abstract][Full Text] [Related]
22. Discovery of [7-(2,6-dichlorophenyl)-5-methylbenzo [1,2,4]triazin-3-yl]-[4-(2-pyrrolidin-1-ylethoxy)phenyl]amine--a potent, orally active Src kinase inhibitor with anti-tumor activity in preclinical assays.
Noronha G; Barrett K; Boccia A; Brodhag T; Cao J; Chow CP; Dneprovskaia E; Doukas J; Fine R; Gong X; Gritzen C; Gu H; Hanna E; Hood JD; Hu S; Kang X; Key J; Klebansky B; Kousba A; Li G; Lohse D; Mak CC; McPherson A; Palanki MS; Pathak VP; Renick J; Shi F; Soll R; Splittgerber U; Stoughton S; Tang S; Yee S; Zeng B; Zhao N; Zhu H
Bioorg Med Chem Lett; 2007 Feb; 17(3):602-8. PubMed ID: 17113292
[TBL] [Abstract][Full Text] [Related]
23. Synthesis and Src kinase inhibitory activity of 2-phenyl- and 2-thienyl-7-phenylaminothieno[3,2-b]pyridine-6-carbonitriles.
Boschelli DH; Wu B; Barrios Sosa AC; Durutlic H; Chen JJ; Wang Y; Golas JM; Lucas J; Boschelli F
J Med Chem; 2005 Jun; 48(11):3891-902. PubMed ID: 15916442
[TBL] [Abstract][Full Text] [Related]
24. The development of 2-benzimidazole substituted pyrimidine based inhibitors of lymphocyte specific kinase (Lck).
Sabat M; VanRens JC; Laufersweiler MJ; Brugel TA; Maier J; Golebiowski A; De B; Easwaran V; Hsieh LC; Walter RL; Mekel MJ; Evdokimov A; Janusz MJ
Bioorg Med Chem Lett; 2006 Dec; 16(23):5973-7. PubMed ID: 16997556
[TBL] [Abstract][Full Text] [Related]
25. Pyrrole derivatives as potent inhibitors of lymphocyte-specific kinase: Structure, synthesis, and SAR.
Takayama T; Umemiya H; Amada H; Yabuuchi T; Shiozawa F; Katakai H; Takaoka A; Yamaguchi A; Endo M; Sato M
Bioorg Med Chem Lett; 2010 Jan; 20(1):108-11. PubMed ID: 19945869
[TBL] [Abstract][Full Text] [Related]
26. Synthesis and SAR of novel imidazoquinoxaline-based Lck inhibitors: improvement of cell potency.
Chen P; Iwanowicz EJ; Norris D; Gu HH; Lin J; Moquin RV; Das J; Wityak J; Spergel SH; de Fex H; Pang S; Pitt S; Shen DR; Schieven GL; Barrish JC
Bioorg Med Chem Lett; 2002 Nov; 12(21):3153-6. PubMed ID: 12372522
[TBL] [Abstract][Full Text] [Related]
27. Discovery of 2-amino-6-carboxamidobenzothiazoles as potent Lck inhibitors.
Huang S; Liu Z; Tian SS; Sandberg M; Spalding TA; Romeo R; Iskandar M; Wang Z; Karanewsky D; He Y
Bioorg Med Chem Lett; 2008 Apr; 18(7):2324-8. PubMed ID: 18353642
[TBL] [Abstract][Full Text] [Related]
28. A-420983: a potent, orally active inhibitor of lck with efficacy in a model of transplant rejection.
Borhani DW; Calderwood DJ; Friedman MM; Hirst GC; Li B; Leung AK; McRae B; Ratnofsky S; Ritter K; Waegell W
Bioorg Med Chem Lett; 2004 May; 14(10):2613-6. PubMed ID: 15109663
[TBL] [Abstract][Full Text] [Related]
29. Synthesis and Src kinase inhibitory activity of a series of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-7-furyl-3-quinolinecarbonitriles.
Boschelli DH; Wu B; Ye F; Wang Y; Golas JM; Lucas J; Boschelli F
J Med Chem; 2006 Dec; 49(26):7868-76. PubMed ID: 17181170
[TBL] [Abstract][Full Text] [Related]
30. SAR of carbon-linked, 2-substituted purines: synthesis and characterization of AP23451 as a novel bone-targeted inhibitor of Src tyrosine kinase with in vivo anti-resorptive activity.
Shakespeare WC; Wang Y; Bohacek R; Keenan T; Sundaramoorthi R; Metcalf C; Dilauro A; Roeloffzen S; Liu S; Saltmarsh J; Paramanathan G; Dalgarno D; Narula S; Pradeepan S; van Schravendijk MR; Keats J; Ram M; Liou S; Adams S; Wardwell S; Bogus J; Iuliucci J; Weigele M; Xing L; Boyce B; Sawyer TK
Chem Biol Drug Des; 2008 Feb; 71(2):97-105. PubMed ID: 18179464
[TBL] [Abstract][Full Text] [Related]
31. N-4-Pyrimidinyl-1H-indazol-4-amine inhibitors of Lck: indazoles as phenol isosteres with improved pharmacokinetics.
Bamborough P; Angell RM; Bhamra I; Brown D; Bull J; Christopher JA; Cooper AW; Fazal LH; Giordano I; Hind L; Patel VK; Ranshaw LE; Sims MJ; Skone PA; Smith KJ; Vickerstaff E; Washington M
Bioorg Med Chem Lett; 2007 Aug; 17(15):4363-8. PubMed ID: 17600705
[TBL] [Abstract][Full Text] [Related]
32. Discovery and SAR of potent, orally available 2,8-diaryl-quinoxalines as a new class of JAK2 inhibitors.
Pissot-Soldermann C; Gerspacher M; Furet P; Gaul C; Holzer P; McCarthy C; Radimerski T; Regnier CH; Baffert F; Drueckes P; Tavares GA; Vangrevelinghe E; Blasco F; Ottaviani G; Ossola F; Scesa J; Reetz J
Bioorg Med Chem Lett; 2010 Apr; 20(8):2609-13. PubMed ID: 20231096
[TBL] [Abstract][Full Text] [Related]
33. QSAR studies on 4-anilino-3-quinolinecarbonitriles as Src kinase inhibitors using robust PCA and both linear and nonlinear models.
Sun M; Zheng Y; Wei H; Chen J; Ji M
J Enzyme Inhib Med Chem; 2009 Oct; 24(5):1109-16. PubMed ID: 19555174
[TBL] [Abstract][Full Text] [Related]
34. Imidazolyl benzimidazoles and imidazo[4,5-b]pyridines as potent p38alpha MAP kinase inhibitors with excellent in vivo antiinflammatory properties.
Mader M; de Dios A; Shih C; Bonjouklian R; Li T; White W; López de Uralde B; Sánchez-Martinez C; del Prado M; Jaramillo C; de Diego E; Martín Cabrejas LM; Dominguez C; Montero C; Shepherd T; Dally R; Toth JE; Chatterjee A; Pleite S; Blanco-Urgoiti J; Perez L; Barberis M; Lorite MJ; Jambrina E; Nevill CR; Lee PA; Schultz RC; Wolos JA; Li LC; Campbell RM; Anderson BD
Bioorg Med Chem Lett; 2008 Jan; 18(1):179-83. PubMed ID: 18039577
[TBL] [Abstract][Full Text] [Related]
35. The development of novel 1,2-dihydro-pyrimido[4,5-c]pyridazine based inhibitors of lymphocyte specific kinase (Lck).
Sabat M; Vanrens JC; Brugel TA; Maier J; Laufersweiler MJ; Golebiowski A; De B; Easwaran V; Hsieh LC; Rosegen J; Berberich S; Suchanek E; Janusz MJ
Bioorg Med Chem Lett; 2006 Aug; 16(16):4257-61. PubMed ID: 16757169
[TBL] [Abstract][Full Text] [Related]
36. Discovery of imidazo[1,5-a]pyrido[3,2-e]pyrazines as a new class of phosphodiesterase 10A inhibitiors.
Höfgen N; Stange H; Schindler R; Lankau HJ; Grunwald C; Langen B; Egerland U; Tremmel P; Pangalos MN; Marquis KL; Hage T; Harrison BL; Malamas MS; Brandon NJ; Kronbach T
J Med Chem; 2010 Jun; 53(11):4399-411. PubMed ID: 20450197
[TBL] [Abstract][Full Text] [Related]
37. Discovery of novel 2,3-diarylfuro[2,3-b]pyridin-4-amines as potent and selective inhibitors of Lck: synthesis, SAR, and pharmacokinetic properties.
Martin MW; Newcomb J; Nunes JJ; Bemis JE; McGowan DC; White RD; Buchanan JL; DiMauro EF; Boucher C; Faust T; Hsieh F; Huang X; Lee JH; Schneider S; Turci SM; Zhu X
Bioorg Med Chem Lett; 2007 Apr; 17(8):2299-304. PubMed ID: 17276681
[TBL] [Abstract][Full Text] [Related]
38. QSAR study of flavonoid derivatives as p56lck tyrosinkinase inhibitors.
Thakur A; Vishwakarma S; Thakur M
Bioorg Med Chem; 2004 Mar; 12(5):1209-14. PubMed ID: 14980632
[TBL] [Abstract][Full Text] [Related]
39. Docking, 3D-QSAR studies and in silico ADME prediction on c-Src tyrosine kinase inhibitors.
Tintori C; Magnani M; Schenone S; Botta M
Eur J Med Chem; 2009 Mar; 44(3):990-1000. PubMed ID: 18722033
[TBL] [Abstract][Full Text] [Related]
40. N-(3-(phenylcarbamoyl)arylpyrimidine)-5-carboxamides as potent and selective inhibitors of Lck: structure, synthesis and SAR.
Deak HL; Newcomb JR; Nunes JJ; Boucher C; Cheng AC; DiMauro EF; Epstein LF; Gallant P; Hodous BL; Huang X; Lee JH; Patel VF; Schneider S; Turci SM; Zhu X
Bioorg Med Chem Lett; 2008 Feb; 18(3):1172-6. PubMed ID: 18083554
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
